| Expression pattern: |
DN |
| Associated gene: |
QKI, ENO1, PI3K, AKT |
| Associated microRNA: |
- |
| Biological function: |
Tumor-suppressive; inhibits GC cell proliferation, migration, invasion and glycolysis. |
| Molecular mechanism: |
circUBE2G1 encodes circUBE2G1-99aa; QKI promotes circUBE2G1 biogenesis; circUBE2G1-99aa binds ENO1 to suppress ENO1 enzymatic activity, inhibiting ENO1/PI3K/AKT signaling and glycolysis. |
| Biological pathway or process: |
glycolysis (inhibits); proliferation (inhibits); migration (inhibits); invasion (inhibits); PI3K/AKT (inhibits) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Transfection; CCK8; Colony Formation Assay; EdU Staining; Transwell Assay; In Vivo Animal Model; Bioinformatics Analysis |
| Clinical significance: |
Lower circUBE2G1 expression correlated with larger tumor size, higher TNM stage, and lymphatic metastasis; circUBE2G1 served as an independent prognostic indicator for diminished survival outcomes. |
| Description: |
circUBE2G1 is down-regulated in gastric cancer and acts as a tumor suppressor mainly through encoding the microprotein circUBE2G1-99aa. circUBE2G1-99aa binds ENO1, inhibits ENO1 enzymatic activity, suppresses glycolysis, and dampens PI3K/AKT signaling, thereby inhibiting proliferation and metastatic phenotypes in vitro and in vivo; low circUBE2G1 is linked to worse clinicopathological features and poorer survival. |
| Confidence score: |
0.7716 |